Pathbreaking HIV drug's generic version to be made in India
To bridge the gap until generic versions become available, Gilead has also committed to supply the product at no profit to ...
MarketWatch4d
Gilead Sciences Inc. stock rises Friday, still underperforms market
Shares of Gilead Sciences Inc. GILD inched 0.33% higher to $84.95 Friday, on what proved to be an all-around great trading ...
FierceBiotech5d
Gilead gives up on $15M MASH bet with Yuhan after mulling preclinical data
In a year that has seen an approval and a raft of readouts for metabolic dysfunction-associated steatohepatitis (MASH), ...
DelveInsight Business Research, LLP: Global Pediatric Drugs Market is Predicted to Resister Growth at a CAGR of ~5% by 2030 | DelveInsight
The growing occurrence of pediatric conditions like HIV, cancer, diabetes, and others is boosting the need for treatments specifically designed for children, making pediatric drug development ...
Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research ...
Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
Gilead Sciences, Inc. (Nasdaq: GILD) today announced additional data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752) providing an overview of the efficacy and safety of twice-yearly lenacapavir ...
Hosted on MSN13d
Indian pharma firms sign deal to produce, sell generic HIV drug lenacapavir
Indian pharmaceutical companies are set to produce generic versions of lenacapavir, an HIV prevention drug, under agreements with US-based Gilead Sciences to distribute it in 120 resource-limited ...
Indiatimes13d
Dr Reddy's enters voluntary licensing deal with Gilead for long-acting HIV drug
Dr. Reddy’s on Wednesday said it has entered into a royalty-free non-exclusive voluntary licensing agreement with Gilead Sciences Ireland for the manufacture and commercialisation of the drug, ...
Gilead signs deals with 6 generic drugmakers to sell HIV drug in low-income countries
Gilead Sciences said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell ...
Ipsen's IQIRVO Approval Has Intensified The Primary Biliary Cholangitis Market Space Delveinsight
The European Commission has granted conditional approval for Ipsen's IQIRVO (elafibranor) for the <a target=_blank href= ...
BioPharma Dive13d
Gilead agrees to license new HIV drug in low-income countries
The company will permit six generic drugmakers to make and sell lenacapavir in 120 countries that have high incidence of the disease, but limited resources.
Gilead Partners 6 Pharma Cos. To Provide Generic Lenacapavir In High-incidence Countries
(RTTNews) - Gilead Sciences, Inc. (GILD) Wednesday said it has signed royalty-free licensing agreements with six pharmaceutical manufacturers to manufacture and supply generic versions of the ...